Full Text Journal Articles in
Journal Mol Cancer

Advertisement

Find full text journal articles






Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring.

Wen Li, Ji-Bin Liu, Li-Kun Hou, Fei Yu, Jie Zhang, Wei Wu, Xiao-Mei Tang, Feng Sun, Hai-Min Lu, Jing Deng, Jie Bai, Juan Li, Chun-Yan Wu, Qin-Lu Lin, Zhong-Wei Lv, Gao-Ren Wang, Geng-Xi Jiang, Yu-Shui Ma, Da Fu,

Primary lung cancer is one of the most common malignant tumors in China. Approximately 60% of lung cancer patients have distant metastasis at the initial diagnosis, so it is necessary to find new tumor markers for early diagnosis and individualized treatment. Tumor markers contribute to the early diagnosis of lung ... Read more >>

Mol Cancer (Molecular cancer)
[2022, 21(1):25]

Cited: 0 times

View full text PDF listing >>



Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy.

Xin Lian, Kailin Yang, Renliang Li, Maomao Li, Jing Zuo, Bohao Zheng, Wei Wang, Ping Wang, Shengtao Zhou,

Cellular metabolism constitutes a fundamental process in biology. During tumor initiation and progression, each cellular component in the cancerous niche undergoes dramatic metabolic reprogramming, adapting to a challenging microenvironment of hypoxia, nutrient deprivation, and other stresses. While the metabolic hallmarks of cancer have been extensively studied, the metabolic states of ... Read more >>

Mol Cancer (Molecular cancer)
[2022, 21(1):27]

Cited: 0 times

View full text PDF listing >>



Advertisement

circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis.

Chonghui Hu, Renpeng Xia, Xiang Zhang, Tingting Li, Yuancheng Ye, Guolin Li, Rihua He, Zhihua Li, Qing Lin, Shangyou Zheng, Rufu Chen,

<h4>Background</h4>Cancer-associated fibroblasts (CAFs) are critically involved in gemcitabine (GEM) resistance in pancreatic ductal adenocarcinoma (PDAC). However, the underlying mechanism by which CAFs promote chemotherapy resistance remains unexplored. Here, we explored the role of circRNAs in CAF-induced GEM resistance in PDAC.<h4>Methods</h4>circRNA sequencing and quantitative real-time PCR (qRT-PCR) were utilized to screen ... Read more >>

Mol Cancer (Molecular cancer)
[2022, 21(1):24]

Cited: 0 times

View full text PDF listing >>



Deep cfDNA fragment end profiling enables cancer detection.

Yulia V Zhitnyuk, Anastasia P Koval, Aleksandr A Alferov, Yanina A Shtykova, Ilgar Z Mamedov, Nikolay E Kushlinskii, Dmitriy M Chudakov, Dmitry S Shcherbo,

Mol Cancer (Molecular cancer)
[2022, 21(1):26]

Cited: 0 times

View full text PDF listing >>



CircMET promotes tumor proliferation by enhancing CDKN2A mRNA decay and upregulating SMAD3.

Lei Yang, Yi Chen, Ning Liu, Yanwen Lu, Wenliang Ma, Zhenhao Yang, Weidong Gan, Dongmei Li,

<h4>Background</h4>Functions of CircMET (hsa_circ_0082002) which is a circular RNA and derived from MET gene remain understood incompletely. In the present study, Xp11.2 translocation/NONO-TFE3 fusion renal cell carcinoma (NONO-TFE3 tRCC) with up-regulated CircMET was employed to investigate its mechanism in cancer progression and post-transcriptional regulation.<h4>Methods</h4>FISH and real-time PCR were performed to ... Read more >>

Mol Cancer (Molecular cancer)
[2022, 21(1):23]

Cited: 0 times

View full text PDF listing >>



A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study.

Kai Li, Yusheng Lin, Yichen Luo, Xiao Xiong, Lu Wang, Kameron Durante, Junkuo Li, Fuyou Zhou, Yi Guo, Shaobin Chen, Yuping Chen, Dianzheng Zhang, Sai-Ching Jim Yeung, Hao Zhang,

<h4>Background</h4>The tRNA-derived small RNAs (tsRNAs) are produced in a nuclease-dependent manner in responses to variety of stresses that are common in cancers. We focus on a cancer-enriched tsRNA signature to develop a salivary exosome-based non-invasive biomarker for human esophageal squamous cell carcinoma (ESCC).<h4>Methods</h4>Cancer-enriched small RNAs were identified by RNA sequencing ... Read more >>

Mol Cancer (Molecular cancer)
[2022, 21(1):21]

Cited: 0 times

View full text PDF listing >>



CircNFIB inhibits tumor growth and metastasis through suppressing MEK1/ERK signaling in intrahepatic cholangiocarcinoma.

Jinpeng Du, Tian Lan, Haotian Liao, Xuping Feng, Xing Chen, Wenwei Liao, Guimin Hou, Lin Xu, Qingbo Feng, Kunlin Xie, Mingheng Liao, Xiangzheng Chen, Jiwei Huang, Kefei Yuan, Yong Zeng,

<h4>Background</h4>Considerable evidence shows that circular RNAs (circRNAs) play an important role in tumor development. However, their function in intrahepatic cholangiocarcinoma (ICC) metastasis and the underlying mechanisms are incompletely understood.<h4>Methods</h4>circNFIB (hsa_circ_0086376, termed as cNFIB hereafter) was identified in human ICC tissues through circRNAs sequencing. The biological role of cNFIB was determined ... Read more >>

Mol Cancer (Molecular cancer)
[2022, 21(1):18]

Cited: 0 times

View full text PDF listing >>



Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.

Ming Yi, Xiaoli Zheng, Mengke Niu, Shuangli Zhu, Hong Ge, Kongming Wu,

Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T cells from exhausted status and revive immune response against cancer cells. Based on the immense success in clinical trials, ten α-PD-1 (nivolumab, pembrolizumab, cemiplimab, sintilimab, camrelizumab, toripalimab, tislelizumab, zimberelimab, prolgolimab, and dostarlimab) and three α-PD-L1 antibodies (atezolizumab, ... Read more >>

Mol Cancer (Molecular cancer)
[2022, 21(1):28]

Cited: 0 times

View full text PDF listing >>



A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients.

Biyun Wang, Yannan Zhao, Yi Li, Yingying Xu, Yun Chen, Qiuyu Jiang, Dingjin Yao, Li Zhang, Xichun Hu, Chaowei Fu, Si Zhang, She Chen,

Mol Cancer (Molecular cancer)
[2022, 21(1):22]

Cited: 0 times

View full text PDF listing >>



Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.

Simona Serratì, Michele Guida, Roberta Di Fonte, Simona De Summa, Sabino Strippoli, Rosa Maria Iacobazzi, Alessandra Quarta, Ivana De Risi, Gabriella Guida, Angelo Paradiso, Letizia Porcelli, Amalia Azzariti,

<h4>Background</h4>The immunotherapy with immune checkpoints inhibitors (ICI) has changed the life expectancy in metastatic melanoma (MM) patients. Nevertheless, several patients do not respond hence, the identification and validation of novel biomarkers of response to ICI is of crucial importance. Circulating extracellular vesicles (EVs) such as PD-L1<sup>+</sup> EV mediate resistance to ... Read more >>

Mol Cancer (Molecular cancer)
[2022, 21(1):20]

Cited: 0 times

View full text PDF listing >>



The role of m6A RNA methylation in cancer metabolism.

Yuanyuan An, Hua Duan,

Metabolic reprogramming is one of the main characteristics of malignant tumors, which is due to the flexible changes of cell metabolism that can meet the needs of cell growth and maintain the homeostasis of tissue environments. Cancer cells can obtain metabolic adaptation through a variety of endogenous and exogenous signaling ... Read more >>

Mol Cancer (Molecular cancer)
[2022, 21(1):14]

Cited: 0 times

View full text PDF listing >>



CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein.

Chi Hin Wong, Ut Kei Lou, Frederic Khe-Cheong Fung, Joanna H M Tong, Chang-Hua Zhang, Ka-Fai To, Stephen Lam Chan, Yangchao Chen,

<h4>Background</h4>Circular RNAs (circRNAs) play important roles in many biological processes. However, the detailed mechanism underlying the critical roles of circRNAs in cancer remains largely unexplored. We aim to explore the molecular mechanisms of circRTN4 with critical roles in pancreatic ductal adenocarcinoma (PDAC).<h4>Methods</h4>CircRTN4 expression level was examined in PDAC primary tumors. ... Read more >>

Mol Cancer (Molecular cancer)
[2022, 21(1):10]

Cited: 0 times

View full text PDF listing >>



Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma.

Florencia Cidre-Aranaz, Jing Li, Tilman L B Hölting, Martin F Orth, Roland Imle, Stefanie Kutschmann, Giulia Ammirati, Katharina Ceranski, Martha Julia Carreño-Gonzalez, Merve Kasan, Aruna Marchetto, Cornelius M Funk, Felix Bestvater, Simone Bersini, Chiara Arrigoni, Matteo Moretti, Uwe Thiel, Daniel Baumhoer, Felix Sahm, Stefan M Pfister, Wolfgang Hartmann, Uta Dirksen, Laura Romero-Pérez, Ana Banito, Shunya Ohmura, Julian Musa, Thomas Kirchner, Maximilian M L Knott, Thomas G P Grünewald,

Mol Cancer (Molecular cancer)
[2022, 21(1):1]

Cited: 0 times

View full text PDF listing >>



circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer.

Yun Ling, Gehao Liang, Qun Lin, Xiaolin Fang, Qing Luo, Yinghuan Cen, Maryam Mehrpour, Ahmed Hamai, Zihao Liu, Yu Shi, Juanmei Li, Wanyi Lin, Shijie Jia, Wenqian Yang, Qiang Liu, Erwei Song, Jun Li, Chang Gong,

<h4>Background</h4>Approximate 25% HER2-positive (HER2<sup>+</sup>) breast cancer (BC) patients treated with trastuzumab recurred rapidly. However, the mechanisms underlying trastuzumab resistance remained largely unclear.<h4>Methods</h4>Trastuzumab-resistant associated circRNAs were identified by circRNAs high-throughput screen and qRT-PCR in HER2<sup>+</sup> breast cancer tissues with different trastuzumab response. The biological roles of trastuzumab-resistant associated circRNAs were detected ... Read more >>

Mol Cancer (Molecular cancer)
[2022, 21(1):8]

Cited: 0 times

View full text PDF listing >>



Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy

Xin Lian, Kailin Yang, Renliang Li, Maomao Li, Jing Zuo, Bohao Zheng, Wei Wang, Ping Wang, Shengtao Zhou,

Cellular metabolism constitutes a fundamental process in biology. During tumor initiation and progression, each cellular component in the cancerous niche undergoes dramatic metabolic reprogramming, adapting to a challenging microenvironment of hypoxia, nutrient deprivation, and other stresses. While the metabolic hallmarks of cancer have been extensively studied, the metabolic states of ... Read more >>

Mol Cancer (Molecular cancer)
[2022, 21(1):]

Cited: 0 times

View full text PDF listing >>



Deep cfDNA fragment end profiling enables cancer detection

Yulia V. Zhitnyuk, Anastasia P. Koval, Aleksandr A. Alferov, Yanina A. Shtykova, Ilgar Z. Mamedov, Nikolay E. Kushlinskii, Dmitriy M. Chudakov, Dmitry S. Shcherbo,

Mol Cancer (Molecular cancer)
[2022, 21(1):]

Cited: 0 times

View full text PDF listing >>



Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC.

Kevin Zhou, Romario Nguyen, Liang Qiao, Jacob George,

Mol Cancer (Molecular cancer)
[2022, 21(1):6]

Cited: 0 times

View full text PDF listing >>



On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.

Tao Jiang, Jianhua Chen, Xingxiang Xu, Ying Cheng, Gongyan Chen, Yueyin Pan, Yong Fang, Qiming Wang, Yunchao Huang, Wenxiu Yao, Rui Wang, Xingya Li, Wei Zhang, Yanjun Zhang, Sheng Hu, Renhua Guo, Jianhua Shi, Zhiwu Wang, Peiguo Cao, Donglin Wang, Jian Fang, Hui Luo, Yi Geng, Chunyan Xing, Dongqing Lv, Yiping Zhang, Junyan Yu, Shundong Cang, Yaxi Zhang, Jiao Zhang, Zeyu Yang, Wei Shi, Jianjun Zou, Caicun Zhou, Shengxiang Ren,

<h4>Background</h4>Camrelizumab plus chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to chemotherapy alone as first-line treatment in advanced lung squamous cell carcinoma (LUSC) in the phase III trial (CameL-sq), which has become an option of standard-of-cares for Chinese patients with advanced LUSC. However, the predictive biomarkers remain ... Read more >>

Mol Cancer (Molecular cancer)
[2022, 21(1):4]

Cited: 0 times

View full text PDF listing >>



A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology.

In-Seob Lee, Zhongxu Zhu, Jeeyun Lee, Joon Oh Park, Xiwei Wu, Tiffany Ong, Sierra Min Li, Xin Wang, Joseph Chao, Ajay Goel,

Mol Cancer (Molecular cancer)
[2022, 21(1):9]

Cited: 0 times

View full text PDF listing >>



Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Ming Yi, Xiaoli Zheng, Mengke Niu, Shuangli Zhu, Hong Ge, Kongming Wu,

Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T cells from exhausted status and revive immune response against cancer cells. Based on the immense success in clinical trials, ten α-PD-1 (nivolumab, pembrolizumab, cemiplimab, sintilimab, camrelizumab, toripalimab, tislelizumab, zimberelimab, prolgolimab, and dostarlimab) and three α-PD-L1 antibodies (atezolizumab, ... Read more >>

Mol Cancer (Molecular cancer)
[2022, 21(1):]

Cited: 0 times

View full text PDF listing >>



circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis

Chonghui Hu, Renpeng Xia, Xiang Zhang, Tingting Li, Yuancheng Ye, Guolin Li, Rihua He, Zhihua Li, Qing Lin, Shangyou Zheng, Rufu Chen,

<h4>Background</h4> Cancer-associated fibroblasts (CAFs) are critically involved in gemcitabine (GEM) resistance in pancreatic ductal adenocarcinoma (PDAC). However, the underlying mechanism by which CAFs promote chemotherapy resistance remains unexplored. Here, we explored the role of circRNAs in CAF-induced GEM resistance in PDAC. <h4>Methods</h4> circRNA sequencing and quantitative real-time PCR (qRT–PCR) were ... Read more >>

Mol Cancer (Molecular cancer)
[2022, 21(1):]

Cited: 0 times

View full text PDF listing >>



Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p.

Yu-Zhong Yu, Dao-Jun Lv, Chong Wang, Xian-Lu Song, Tao Xie, Tao Wang, Zhi-Min Li, Jia-Ding Guo, Du-Jiang Fu, Kang-Jin Li, Ding-Lan Wu, Franky Leung Chan, Ning-Han Feng, Zhe-Sheng Chen, Shan-Chao Zhao,

<h4>Background</h4>More and more studies have shown that circular RNAs (circRNAs) play a critical regulatory role in many cancers. However, the potential molecular mechanism of circRNAs in prostate cancer (PCa) remains largely unknown.<h4>Methods</h4>Differentially expressed circRNAs were identified by RNA sequencing. The expression of hsa_circ_0003258 was evaluated using quantitative real-time PCR and ... Read more >>

Mol Cancer (Molecular cancer)
[2022, 21(1):12]

Cited: 0 times

View full text PDF listing >>



Correction to: Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl.

Zhongzheng Lu, Yanli Jin, Chun Chen, Juan Li, Qi Cao, Jingxuan Pan,

Mol Cancer (Molecular cancer)
[2021, 20(1):172]

Cited: 0 times

View full text PDF listing >>



Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies.

Thomas Dillinger, Raheleh Sheibani-Tezerji, Walter Pulverer, Ines Stelzer, Melanie R Hassler, Janine Scheibelreiter, Carlos Uziel Pérez Malla, Madeleine Kuroll, Sandra Domazet, Elisa Redl, Sarah Ely, Stefanie Brezina, Andreas Tiefenbacher, Katharina Rebhan, Nicolai Hübner, Bernhard Grubmüller, Markus Mitterhauser, Marcus Hacker, Andreas Weinhaeusel, Judit Simon, Markus Zeitlinger, Andrea Gsur, Gero Kramer, Shahrokh F Shariat, Lukas Kenner, Gerda Egger,

Mol Cancer (Molecular cancer)
[2022, 21(1):7]

Cited: 0 times

View full text PDF listing >>



Correction to: Long non-coding RNA UCA1 promotes malignant phenotypes of renal cancer cells by modulating the miR-182-5p/DLL4 axis as a ceRNA.

Wei Wang, Wentao Hu, Ya Wang, Yong An, Lei Song, Panfeng Shang, Zhongjin Yue,

Mol Cancer (Molecular cancer)
[2022, 21(1):3]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

1.0134 s